Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT-013 in Hidradenitis Suppurativa
NCT06993233Phase 2Active, not recruiting
- Sponsor
- Citryll
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of CIT013 in hidradenitis suppurativa (HS), sponsored by Citryll. Started Oct 2025; status: active, not recruiting.
02
Drugs
CIT013
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06993233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993233.